NASDAQ$OABI

OmniAb Inc · Q3 2025 earnings

Q3 2025 earnings · · After market close · Investor relations

Briefing

OmniAb reported Q3 2025, revenue of $2.2M, a net loss of $16.5M, diluted EPS of $-0.14.

For Q3 2025, OmniAb reported revenue of $2.2M, a net loss of $16.5M, diluted EPS of $-0.14. Management discussed operating trends, liquidity, and priorities as disclosed in the quarterly filing.

  • Revenue $2.2M.
  • Net loss $16.5M.
  • Diluted EPS $-0.14.

Headline financials

Total Revenue

$2.24M

Previous: $4.17M-46.3%
EPS (adj)

-$0.14

Previous: -$0.16+12.5%
Capital Expenditures

-$556K

Previous: -$1.83M+69.6%
Free Cash Flow

-$31.3M

Previous: -$37.6M+16.7%
Net Income

-$16.5M

Previous: -$16.4M-0.9%
Operating Income

-$18.1M

Previous: -$19.8M+8.2%

Revenue & EPS history

OmniAb · Revenue · Quarterly

$2.24M

Q3 2025-46.3%vs Q3 2024
Beat estimate in 4 of 13 quarters(31%)
ActualEstimate

Revenue by segment

OmniAb · $5.48M total across 3 segments · Q3 2023

  • Service Revenue
    $3.02M
  • License and Milestone
    $2.01M
  • Royalty Revenue
    $451K

Forward guidance

The filing discusses OmniAb's outlook, capital deployment, and key risks without relying solely on numeric EPS guidance.

Tailwinds

  • OmniAb cited execution on strategic priorities in the filing.
  • Balance sheet and liquidity support continued operations.
  • Pipeline milestones and partnerships remain key value drivers.

Headwinds

  • GAAP profitability remained under pressure in the quarter.
  • Macro, competitive, and cost pressures may affect margins.
  • Segment mix and one-time items can affect comparability.
  • Clinical or pre-commercial spend continues ahead of sustainable revenue.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 17 quarterly earnings reports · overlaid with Q3 2025

Historical avgQ3 2025

-2.1%

Avg return

Earnings day

+1.5%

Avg return

5 days after

+4.1%

Avg return

30 days after

39%

7 / 18 earnings

Positive

+9.9%

Q4 2025

Best reaction

-20.4%

Q4 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+2.1%+29.4%+72.7%
Q4 2025+9.9%+9.9%-14.9%
Q3 2025-4.1%+0.7%+31.8%
Q1 2025-7.2%-3.2%-4.5%
Q4 2024-20.4%-20.4%-43.9%
Q3 2024-11.5%-15.7%-13.0%
Q2 2024+4.4%+4.9%-2.2%
Q1 2024+3.1%-0.9%+2.2%
Q4 2023-2.5%+0.8%-11.4%
Q3 2023-6.8%+3.5%+7.3%
Q2 2023-5.7%-3.8%-10.4%
Q1 2023+6.1%+16.1%+37.3%
Q4 2022+9.5%+10.1%+3.6%
Q3 2022-15.5%-4.1%+19.3%
Q2 2022+0.2%+0.1%+0.3%
Q1 2022-0.0%+0.0%+0.1%
Q4 2021-0.0%-0.1%-0.1%
Q3 2021+0.0%+0.0%-0.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro